CBP-233 is a humanized antibody targeting IL-33 that we intend to develop for the treatment of Th2 inflammatory diseases.

Preliminary evidence of the therapeutic potential of an anti-IL-33 antibody has been reported in several indications including asthma, AD, and food allergy. We are currently conducting preclinical studies to support a future Investigational New Drug Application submission of CBP-233 with the FDA.

Target Indication

Allergic inflammation